01 Expansion of Minimally Invasive Trigeminal Nerve Procedures The trigeminal neuralgia treatment market trends show that the need for effective pain control with lower procedural burden is shifting treatment toward minimally invasive options such as radiofrequency ablation, balloon compression, and glycerol rhizotomy. This transition supports treatment for patients who may not be suitable for open surgery, while a systematic review of 37 studies involving 3,288 patients evaluated stereotactic radiosurgery and neuroablative procedures as less-invasive approaches for medically refractory TN. The outcome is broader use of percutaneous and other minimally invasive procedures for recurrent or medication-refractory trigeminal neuralgia.
02 Adoption of Stereotactic Radiosurgery for Medication-Refractory TN The trigeminal neuralgia treatment market trends show that persistent pain despite medication is shifting treatment toward stereotactic radiosurgery (SRS), including Gamma Knife and other focused radiation systems. This transition provides a noninvasive treatment option for selected patients, with a 2025 meta-analysis covering 3,288 patients reporting pain-free outcomes alongside lower rates of some adverse effects compared with neuroablative procedures. The outcome is greater use of SRS as a treatment option for patients with medication-refractory TN, particularly when less-invasive management is preferred.
01 Pharmacological Pain Management Demand and Neuropathic Drug Formulation Advances Drive Market Higher demand for pharmacological pain management is supporting the use of medicines for patients seeking relief from trigeminal neuralgia symptoms. A 2026 systematic review covering more than 170 million participants and 109,070 patients estimated global TN incidence at 25.33 cases per 100,000 person-years and annual prevalence at 45.38 cases per 100,000 inhabitants, indicating a measurable treatment population. Carbamazepine remains an established pharmacological treatment for TN, with NICE recognizing its long-standing role in clinical practice. For example, carbamazepine is used to control the severe facial pain associated with trigeminal neuralgia.Advances in neuropathic pain drug formulations are strengthening the supply of treatment options for patients who require sustained symptom management. NICE identifies carbamazepine as the established treatment for TN, while clinical guidance also recognizes oxcarbazepine as an alternative that may offer better tolerability for some patients. The availability of different formulations and dosing approaches can support treatment personalization and improve medication management. For example, FDA labeling for carbamazepine includes immediate-release and extended-release tablets, with maintenance doses commonly ranging from 400–800 mg per day when clinically appropriate.
01 Limited Treatment Efficacy and Treatment-Related Complications Restrain Trigeminal Neuralgia Treatment Market Expansion Limited treatment efficacy in refractory patients can restrict the adoption of available therapies when pain persists despite medication or repeated interventions. Treatment resistance can require changes in medication, combination therapies, or invasive procedures, increasing the complexity and duration of care. These limitations can reduce patient confidence, increase treatment burden, and restrain Trigeminal Neuralgia Treatment Market growth.Treatment-related complications can create concerns around surgical and interventional options used for difficult-to-treat cases. Procedures such as microvascular decompression and ablative treatments may involve risks including facial numbness, sensory changes, or other neurological complications. Such risks can make patients and physicians more cautious about advanced interventions and limit wider adoption in the trigeminal neuralgia treatment market.
01 Botulinum Toxin and Personalized Diagnosis Create New Market Opportunities Neurology clinics, pain specialists, and botulinum toxin manufacturers benefit from targeted treatment options for selected trigeminal neuralgia patients. Companies such as AbbVie and Ipsen can generate revenue through specialized injection therapies and clinical partnerships, while 2026 evidence reports potential pain reduction with botulinum toxin in trigeminal neuralgia.Neurology centers, radiology providers, and medical-imaging companies benefit from patient-specific diagnosis and treatment planning using advanced MRI. A 2026 systematic review found that 3.0-T MRI and advanced sequences improve visualization of neurovascular conflicts, creating revenue through specialized imaging, diagnostic services, and treatment-planning solutions that support trigeminal neuralgia (TN) treatment market growth.
01 Delayed Diagnosis and Limited Specialist Access Hinder Trigeminal Neuralgia Treatment Market Growth Delayed diagnosis makes it difficult for treatment providers to intervene early because TN symptoms can resemble dental disorders, migraine, or other facial-pain conditions. The NHS notes that patients may undergo repeated dental procedures before receiving the correct diagnosis, increasing treatment delays and limiting timely demand for specialized TN therapies.Limited access to neurologists, neurosurgeons, and specialized facial-pain centers restricts treatment availability, particularly in rural and underserved areas. For example, the U.S. National Institute of Neurological Disorders and Stroke identifies TN as a condition that can require specialist evaluation and multiple diagnostic approaches, making coordinated access to appropriate expertise important for broader treatment adoption.
May 2026 – NeuroOne Reports Successful Clinical Use of OneRF® Trigeminal Nerve Ablation SystemNeuroOne Medical Technologies announced that its OneRF® Trigeminal Nerve Ablation System had been used in 16 trigeminal neuralgia procedures, with all treated patients reported to be pain-free following the procedure.
April 2026 – New Mayo Clinic Review Highlights Emerging Therapies for Refractory Trigeminal NeuralgiaResearchers from the Mayo Clinic published a review highlighting promising treatment options including lacosamide, eslicarbazepine, botulinum toxin, and investigational therapies such as vixotrigine (BIIB074) and basimglurant for patients with refractory trigeminal neuralgia.
March 2026 – AIIMS Gorakhpur Launches Advanced Radiofrequency Ablation Facility for Chronic Pain ManagementAIIMS Gorakhpur introduced an advanced radiofrequency ablation (RFA) facility capable of treating trigeminal neuralgia and other chronic pain disorders using conventional, cooled, and pulsed RFA technologies, expanding access to minimally invasive pain management in India.
August 2025 – NeuroOne Receives FDA Clearance for OneRF® Trigeminal Nerve Ablation SystemNeuroOne Medical Technologies received U.S. FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System, designed to create radiofrequency lesions for treating trigeminal neuralgia and other functional neurosurgical procedures. The company announced a limited commercial launch for the fourth quarter of 2025.